{"id":39691,"date":"2026-10-05T11:21:00","date_gmt":"2026-10-05T15:21:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39691"},"modified":"2026-09-23T21:19:04","modified_gmt":"2026-09-24T01:19:04","slug":"your-formulary-committee-is-budgeting-around-a-patent-date-thats-already-been-extended-twice","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/your-formulary-committee-is-budgeting-around-a-patent-date-thats-already-been-extended-twice\/","title":{"rendered":"Your Formulary Committee Is Budgeting Around a Patent Date That’s Already Been Extended Twice"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Enbrel’s first composition patent expired in 2010. The drug is still exclusive in the United States sixteen years later, and will stay that way until at least April 2029. Two FDA-approved biosimilars, Sandoz’s Erelzi and Samsung Bioepis’s Eticovo, have been sitting under permanent injunctions since 2019, unable to ship a single vial. A third legal round, an antitrust suit meant to force the date forward, was dismissed in February 2026 and is now on appeal. If your health system’s biosimilar savings model still treats 2029 as a hard stop, it is worth checking which patent that date actually comes from, because Amgen has moved it twice already and is currently defending it a third time.<\/p>\n\n\n\n

The Short Answer<\/strong><\/h2>\n\n\n\n

Enbrel (etanercept) launched in the U.S. on November 6, 1998. [1] Its original composition-of-matter patent, filed in 1990, expired in 2010. [2] Two secondary patents, U.S. Patent 8,063,182 (issued November 22, 2011) and U.S. Patent 8,163,522, pushed exclusivity to November 2028 and then April 2029. [3][1] Both patents came from a licensing deal Amgen struck with Hoffmann-La Roche, not from any new invention Amgen made after 2010. Federal courts have upheld both patents twice: once in the original infringement litigation (2019-2021) and again in February 2026, when a Virginia federal court dismissed Sandoz’s antitrust challenge to the same patents. [4] Sandoz has appealed that dismissal to the Fourth Circuit, and the case is active as of this writing. [5]<\/p>\n\n\n\n

The Five Findings That Matter<\/strong><\/h2>\n\n\n\n
    \n
  • Enbrel’s biosimilar-blocking exclusivity in the U.S. now runs through April 2029, 31 years after launch, versus a European patent expiration in the mid-2010s that let biosimilars launch there in early 2016. [6][2]<\/li>\n\n\n\n
  • The two patents actually enforced against biosimilars in court, the ‘182 and ‘522 patents, were not new Amgen inventions. Amgen paid Roche for an exclusive license to a patent application Roche had already filed, and the patents issued nine and ten years after Enbrel’s original patent term would have run out. [1][7]<\/li>\n\n\n\n
  • I-MAK’s patent count for Enbrel grew from 57 U.S. patents identified in a 2018 audit to 154 patent applications (74 granted) identified in a February 2025 update, a figure the group says amounts to 49.7 years of cumulative patent protection on one drug. [2][8]<\/li>\n\n\n\n
  • Two biosimilars have held FDA approval since 2016 and 2019, respectively, and have not sold a single dose in the United States because of permanent injunctions tied to the ‘182 and ‘522 patents. [6][7][9]<\/li>\n\n\n\n
  • Sandoz’s 2025 antitrust suit, dismissed in February 2026, was not defeated on the merits of whether Amgen’s conduct was anticompetitive. It was dismissed because the court found Sandoz should have raised the same argument as a counterclaim in the 2016-2020 patent case, and because patent enforcement is generally immune from antitrust liability under the Noerr-Pennington doctrine. [4]<\/li>\n<\/ul>\n\n\n\n

    Enbrel’s Patent Timeline: From a 2010 Expiration to an April 2029 Injunction<\/strong><\/h2>\n\n\n\n

    The Original Composition Patent (Filed 1990, Expired 2010)<\/strong><\/h3>\n\n\n\n

    Enbrel is a fusion protein: the extracellular portion of the human p75 tumor necrosis factor receptor linked to the Fc region of human IgG1. [10] The FDA first approved it in November 1998 for rheumatoid arthritis, and it went on to become one of the first biologic blockbusters, crossing $1 billion in global sales by 2002. [6] According to I-MAK’s patent audit, the primary patent covering that molecule was filed in 1990 and expired in 2010, which is the date most contemporary analyses treated as Enbrel’s real patent cliff. [2] A separate line of reporting, drawing on academic literature published in 2014, describes “a key etanercept patent” as due to expire in 2012. [11] The two figures likely refer to different patents within the same original filing family; either way, every account agrees the foundational patent had run its course by 2012 at the latest.<\/p>\n\n\n\n

    The First Extension: U.S. Patent 8,063,182<\/strong><\/h3>\n\n\n\n

    On November 22, 2011, the U.S. Patent and Trademark Office issued Patent 8,063,182, covering the etanercept fusion protein itself. Amgen did not invent this patent. Immunex, which Amgen acquired in 2002, had licensed the underlying patent application from Hoffmann-La Roche back in 1999. In 2004, two years after buying Immunex, Amgen paid Roche a one-time fee for an exclusive, fully paid-up license to that application. Seven years later, the application issued as the ‘182 patent, with a 17-year term running from its 2011 issue date rather than from its original 1990s filing date. That gave Amgen protection through November 22, 2028, sixteen to eighteen years past the original composition patent’s expiration. [1]<\/p>\n\n\n\n

    The Second Extension: U.S. Patent 8,163,522<\/strong><\/h3>\n\n\n\n

    A second Roche-originated patent, 8,163,522, covers a manufacturing method for etanercept. It carries a later expiration date, April 24, 2029, and it is this patent, not the ‘182 patent, that now sets the effective date on which Erelzi and Eticovo may enter the U.S. market. [7][3] Legal filings refer to the ‘182 and ‘522 patents collectively as the “Brockhaus Patents,” after the named inventor on the original Roche applications. [5] Together they moved Enbrel’s U.S. exclusivity from a 2010-2012 expiration to an April 2029 injunction date, a nineteen-year extension achieved through two sequential patents licensed from a third party rather than through any single act of invention by Amgen after Enbrel’s launch.<\/p>\n\n\n\n

    Where the Brockhaus Patents Came From: The 2004 Roche Deal<\/strong><\/h3>\n\n\n\n

    The mechanism matters for anyone trying to model when the next “surprise” extension might arrive. Amgen’s exclusivity was not extended by Amgen filing new patent applications on new Enbrel research. It was extended by Amgen buying exclusive rights to Roche’s existing, already-filed patent applications and then waiting for the U.S. Patent Office to grant them, sometimes over a decade after they were filed. That is a purchasable, not just an inventable, source of exclusivity, and it is central to Sandoz’s later antitrust theory. [1][5]<\/p>\n\n\n\n

    What the Original Formulary Models Got Wrong<\/strong><\/h2>\n\n\n\n

    The BPCIA’s 12-Year Exclusivity Clock Never Applied to Enbrel<\/strong><\/h3>\n\n\n\n

    The Biologics Price Competition and Innovation Act of 2009 gives new biologics 12 years of regulatory exclusivity from FDA approval before a biosimilar can be licensed. [6] Enbrel launched in 1998, eleven years before that statute existed, so the 12-year clock is irrelevant to it. Any formulary model that estimated Enbrel’s loss-of-exclusivity date by adding 12 years to the 1998 approval, or that assumed BPCIA exclusivity was the operative constraint at all, was modeling the wrong mechanism. The actual constraint has always been patents, not regulatory exclusivity, and patents on biologics can be filed and granted years or decades after launch.<\/p>\n\n\n\n

    Europe’s Divergent Timeline: Biosimilars by Early 2016<\/strong><\/h3>\n\n\n\n

    In the European Union, etanercept’s core patent protection ran out earlier, and biosimilars entered the market in early 2016. [6] Within about two years, biosimilar competition cut European prices by close to half and captured roughly 40 percent market share. [2] Pfizer, which markets Enbrel outside the U.S. and Canada, saw its ex-U.S. Enbrel revenue fall from a peak of $3.8 billion in 2014 to $2.9 billion within two years and to roughly $690 million more recently, a decline Sandoz cited directly in its antitrust complaint as evidence of what U.S. patients and payers are missing. [5] A U.S. formulary team benchmarking against the European timeline, a common practice for globally sold biologics, would have expected an early- to mid-2010s entry date. That expectation was correct for the original patent and wrong for the country.<\/p>\n\n\n\n

    U.S. Payers Modeled Off the Wrong Expiration Date<\/strong><\/h3>\n\n\n\n

    Put together, a payer building a biosimilar savings model around 2012 (the widely cited “original” expiration), around 2016 (the European precedent), or even around 2020 (a reasonable buffer after Erelzi’s 2016 approval) would have been wrong by anywhere from nine to seventeen years. The actual controlling date, April 2029, was not set by the underlying science of the molecule. It was set by two patents that did not exist, in issued form, until 2011 and sometime shortly after.<\/p>\n\n\n\n

    The Litigation Timeline: How Two Biosimilars Got Boxed Out<\/strong><\/h2>\n\n\n\n

    Erelzi’s Approval and Amgen v. Sandoz<\/strong><\/h3>\n\n\n\n

    The FDA approved Sandoz’s Erelzi (etanercept-szzs) on August 30, 2016, following a unanimous 20-0 recommendation from the agency’s Arthritis Advisory Committee. [6][12] Amgen sued Sandoz for infringement in the U.S. District Court for the District of New Jersey shortly after approval, in Case No. 2:16-cv-01118, asserting the ‘182 and ‘522 patents along with several others. [4]<\/p>\n\n\n\n

    The August 2019 District Court Ruling<\/strong><\/h3>\n\n\n\n

    In August 2019, the district court ruled for Amgen, finding the ‘182 and ‘522 patents valid and infringed. [3] Sandoz had argued the patents were invalid for obviousness-type double patenting, essentially that Amgen was using a second patent to cover the same invention as an earlier, expired one, and lost.<\/p>\n\n\n\n

    The July 2020 Federal Circuit Decision<\/strong><\/h3>\n\n\n\n

    Sandoz appealed, and in July 2020 the U.S. Court of Appeals for the Federal Circuit affirmed the district court in a 2-1 decision, holding that Sandoz had not shown the asserted claims invalid. [13][4] The ruling triggered a permanent injunction barring Erelzi’s U.S. commercial launch until the ‘182 and ‘522 patents expire.<\/p>\n\n\n\n

    The May 2021 Supreme Court Denial<\/strong><\/h3>\n\n\n\n

    Sandoz petitioned the U.S. Supreme Court for certiorari, arguing that “patentees may not obtain two patents on the same invention.” [9] In May 2021, the Court declined to hear the case, closing off Sandoz’s direct appeal route. Sandoz US president Keren Haruvi said at the time that the ruling meant Erelzi “will not be available to U.S. patients… until 2029.” [14]<\/p>\n\n\n\n

    Eticovo’s Parallel Case<\/strong><\/h3>\n\n\n\n

    Samsung Bioepis’s Eticovo (etanercept-ykro) received FDA approval on April 25, 2019, as the second etanercept biosimilar cleared for the U.S. market. [15][7] Amgen filed a separate BPCIA infringement suit against Samsung Bioepis in the same New Jersey district court, Case No. 2:19-cv-11755, again asserting the ‘182 and ‘522 patents. [4] On November 3, 2021, the district court ruled for Amgen, Immunex, and Roche, and Samsung Bioepis stipulated to infringement rather than pursue a second appeal through the same losing arguments Sandoz had already exhausted. [9][4] A permanent injunction now bars Eticovo from the U.S. market on the same terms as Erelzi, until April 2029.<\/p>\n\n\n\n

    Round Two: Sandoz’s 2025 Antitrust Challenge<\/strong><\/h2>\n\n\n\n

    The Brockhaus Patent Antitrust Theory<\/strong><\/h3>\n\n\n\n

    In April 2025, Sandoz filed a new complaint against Amgen in the U.S. District Court for the Eastern District of Virginia, Case No. 2:25-cv-00218. [4] This was not a patent-invalidity argument. Sandoz alleged violations of the Sherman Act and New Jersey state antitrust law, arguing that Amgen’s 2004 purchase of the Brockhaus Patents from Roche was itself an anticompetitive act, one that let Amgen “unlawfully extend its monopoly” on Enbrel well beyond what the original patents would have allowed. [16] Sandoz argued that absent Amgen’s acquisition of those Roche patent rights, biosimilar competition could have reached the U.S. market by 2019, when other Amgen patents on Enbrel expired, mirroring the timeline Sandoz achieved in Europe. [5]<\/p>\n\n\n\n

    The February 2026 Dismissal<\/strong><\/h3>\n\n\n\n

    On February 17, 2026, the Eastern District of Virginia dismissed Sandoz’s complaint for failure to state a claim under Federal Rule of Civil Procedure 12(b)(6). [4] The court’s reasoning rested on two doctrines rather than on the underlying question of whether buying a competitor’s patent rights to block biosimilars is procompetitive or anticompetitive. First, it held that Amgen’s patent prosecution and enforcement activity was protected under the Noerr-Pennington doctrine, which shields government petitioning conduct, including patent litigation, from antitrust liability. [17] Second, and more consequentially for future cases, it found that Sandoz’s claim about the Roche patent acquisition should have been raised as a compulsory counterclaim back in the original 2016-2020 infringement suit, since it arose from the same transaction or occurrence under Federal Rule of Civil Procedure 13(a). [4]<\/p>\n\n\n\n

    The Compulsory-Counterclaim Problem<\/strong><\/h3>\n\n\n\n

    That second finding is the one worth watching. If it stands, it effectively means a defendant in a biosimilar patent suit has one shot: any antitrust theory about how the asserted patents were acquired has to be raised inside that original litigation or it is waived permanently, regardless of when the underlying facts about the acquisition become clear. Sandoz argues this reasoning would let defendants like Amgen escape antitrust scrutiny of patent-acquisition conduct entirely, since such conduct is rarely central to, or even discoverable within, an infringement defense. [18]<\/p>\n\n\n\n

    Sandoz’s Fourth Circuit Appeal and the Amicus Fight<\/strong><\/h3>\n\n\n\n

    Sandoz filed a notice of appeal on March 13, 2026, taking the case to the U.S. Court of Appeals for the Fourth Circuit. [5] By July 2026, the appeal had drawn amicus briefs from PhRMA, the Biotechnology Innovation Organization, and retired Federal Circuit Chief Judge Paul Michel, all opposing Sandoz’s position and warning that treating patent-acquisition antitrust claims as compulsory counterclaims elsewhere, or reviving them years later, would multiply litigation across the biopharmaceutical industry. [19] As of this writing, the Fourth Circuit has not ruled, and the April 2029 injunction date remains in force for both Erelzi and Eticovo.<\/p>\n\n\n\n

    How Many Patents Actually Protect Enbrel?<\/strong><\/h2>\n\n\n\n

    I-MAK’s Patent Count: From 57 to 154<\/strong><\/h3>\n\n\n\n

    The nonprofit Initiative for Medicines, Access & Knowledge (I-MAK) has tracked Enbrel’s patent estate in two major snapshots. Its November 2018 report, “Overpatented, Overpriced: Enbrel Special Edition,” found 57 patents filed on Enbrel in the U.S., compared with 20 in Europe and 18 in Japan, and calculated that the combined patents delayed biosimilar competition by 39 years versus the 20-year term a single patent would provide. [2][8] A February 2025 update to I-MAK’s Drug Patent Book database put the figure at 154 U.S. patent applications filed on Enbrel, of which 74 have been granted, for a combined 49.7 years of patent protection on one molecule. [20]<\/p>\n\n\n\n

    \n

    I-MAK’s 2025 patent-landscape update counts 154 U.S. patent applications filed on Enbrel, 74 of which have been granted, together providing 49.7 years of patent protection, roughly two and a half times the 20-year term a single U.S. patent normally carries. (I-MAK, 2025)<\/p>\n<\/blockquote>\n\n\n\n

    Original Analysis: Patents Filed Before vs. After FDA Approval<\/strong><\/h3>\n\n\n\n

    I-MAK’s 2018 report found that Amgen filed 72 percent of its total Enbrel patent applications after the drug had already received FDA approval in 1998. [8] Read against the ‘182 and ‘522 patent timeline above, that statistic is consistent with what actually blocked biosimilar entry: not a pre-launch invention, but a post-launch acquisition of someone else’s patent application, prosecuted to issuance more than a decade after Enbrel first reached patients.<\/p>\n\n\n\n

    Patents Filed 1990-2004<\/strong><\/h4>\n\n\n\n

    This earlier window covers the original composition-of-matter patent family, filed starting in 1990, and the period during which Immunex licensed and Amgen later acquired the Roche patent rights that would become the ‘182 and ‘522 patents.<\/p>\n\n\n\n

    Patents Filed 2005-2018<\/strong><\/h4>\n\n\n\n

    The bulk of the post-approval filings I-MAK identified fall in this window, covering manufacturing process refinements, formulation changes, and method-of-use claims filed well after Enbrel’s initial approval and well after the original composition patent had already expired.<\/p>\n\n\n\n

    The Counterargument: Why Raw Patent Counts Can Mislead<\/strong><\/h3>\n\n\n\n

    I-MAK’s methodology is not uncontested. An October 2025 critique from IPWatchdog argued that I-MAK’s broader “Overpatented, Overpriced” series, including its 2025 work on other drugs, uses an “overly broad” search strategy that inflates patent counts by including applications that never issued, patents with narrow or non-blocking claims, and filings that do not actually extend commercial exclusivity. [21] The critique cites a USPTO Drug Patent and Exclusivity Study noting that “simply quantifying raw numbers of patents and exclusivities is an imprecise way to measure the intellectual property landscape of a drug product because not every patent or exclusivity has the same scope.” [21] That is a fair caution for Enbrel specifically: of the 74 granted patents I-MAK counts as of 2025, only two, the ‘182 and ‘522 patents, have actually been litigated to a final injunction against biosimilars. The other 72 may contribute to the underlying wall of exclusivity in ways not yet tested in court, or they may be largely irrelevant to the practical entry date. Formulary teams modeling risk should weight the two enforced, injunction-bearing patents far more heavily than the raw patent count.<\/p>\n\n\n\n

    What This Delay Has Cost the U.S. Health System<\/strong><\/h2>\n\n\n\n

    Documented Cost Impacts, 2012-2019<\/strong><\/h3>\n\n\n\n

    Medicare and Medicaid Spending<\/strong><\/h4>\n\n\n\n

    I-MAK’s 2018 report, drawing on CMS drug spending data, found that combined Medicare and Medicaid spending on Enbrel rose 129 percent between 2012 and 2016, totaling $7.7 billion in taxpayer funds over that period. Average annual Medicare spending per Enbrel patient nearly doubled over the same window, from $16,828 to $32,891. [2][8]<\/p>\n\n\n\n

    U.S. List Price Trend<\/strong><\/h4>\n\n\n\n

    Independent reporting put Enbrel’s average U.S. cost at $2,225 per month in 2013 and an estimated $4,944.95 per month by 2019, more than doubling over six years without any biosimilar competition to constrain the increases. [14][7]<\/p>\n\n\n\n

    The European Counterfactual<\/strong><\/h3>\n\n\n\n

    Price Decline After the 2016 Biosimilar Launch<\/strong><\/h4>\n\n\n\n

    European biosimilar entry in early 2016 cut Enbrel’s price by nearly half within two years. [2]<\/p>\n\n\n\n

    Market Share Shift<\/strong><\/h4>\n\n\n\n

    Biosimilars captured roughly 40 percent of the European etanercept market within that same two-year window, a share the U.S. market has never seen because no biosimilar has ever legally launched there. [2] Sandoz has estimated a U.S. Erelzi launch could save the health system roughly $1 billion per year, a figure it has repeated in both its earlier public statements and its 2025 antitrust filings. [13]<\/p>\n\n\n\n

    Enbrel and Its Blocked Biosimilars: A Side-by-Side Comparison<\/strong><\/h2>\n\n\n\n
    Product<\/th>Company<\/th>FDA Approval<\/th>U.S. Commercial Status<\/th>Governing Patents<\/th>Earliest Legal U.S. Entry<\/th><\/tr><\/thead>
    Enbrel (etanercept)<\/td>Amgen (Immunex\/Roche origin)<\/td>Approved November 1998<\/td>On market, sole U.S. supplier<\/td>US 8,063,182; US 8,163,522<\/td>N\/A (reference product)<\/td><\/tr>
    Erelzi (etanercept-szzs)<\/td>Sandoz<\/td>Approved August 30, 2016<\/td>Approved, not launched; permanent injunction<\/td>Blocked by US 8,063,182; US 8,163,522<\/td>April 2029<\/td><\/tr>
    Eticovo (etanercept-ykro)<\/td>Samsung Bioepis<\/td>Approved April 25, 2019<\/td>Approved, not launched; permanent injunction<\/td>Blocked by US 8,063,182; US 8,163,522<\/td>April 2029<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Source: compiled from court filings and reporting cited throughout this article. [4][6][7][15]<\/em><\/p>\n\n\n\n

    What Happens If Sandoz Wins on Appeal?<\/strong><\/h2>\n\n\n\n

    Scenario 1: The Fourth Circuit Reverses<\/strong><\/h3>\n\n\n\n

    If the Fourth Circuit revives Sandoz’s antitrust claim, the case returns to the district court for discovery and trial on the merits, a process that would likely take one to three years before any judgment, let alone an injunction reopening the market. A reversal would not itself move the 2029 date; it would only restore Sandoz’s opportunity to argue, with evidence, that the date should never have been set that far out. This is a live legal question, not a settled outcome, and formulary teams should treat any pre-2029 entry as a contingency to monitor rather than a plan to budget around.<\/p>\n\n\n\n

    Scenario 2: The April 2029 Date Holds<\/strong><\/h3>\n\n\n\n

    If the dismissal is affirmed, or if Sandoz’s appeal fails on the compulsory-counterclaim theory specifically, the practical effect is the same as it has been since 2021: no etanercept biosimilar enters the U.S. market before the ‘522 patent expires in April 2029, absent a settlement between the parties. Amgen itself has told investors to expect continued declining net selling price and roughly flat volumes for Enbrel through 2025, suggesting the company is already managing the product for its final years of exclusivity rather than for growth. [15]<\/p>\n\n\n\n

    What This Means for Formulary Committees and P&T Budgets<\/strong><\/h2>\n\n\n\n

    Rebuilding the Biosimilar Savings Model<\/strong><\/h3>\n\n\n\n

    A defensible Enbrel model for 2026 and beyond should anchor on April 2029 as the base case, note that this date has already survived one Federal Circuit appeal, one Supreme Court cert denial, and one district court antitrust dismissal, and treat any earlier entry as upside risk tied to a specific, trackable event: a Fourth Circuit reversal, or a negotiated settlement between Amgen and either biosimilar maker. Given that Amgen negotiated settled entry dates with generic and biosimilar challengers on other products rather than litigating every case to the injunction date, a settlement remains possible and would likely be announced with more lead time than a court ruling.<\/p>\n\n\n\n

    A Framework for Auditing Other “Locked” Biologics<\/strong><\/h3>\n\n\n\n

    Enbrel is a useful template for auditing any other biologic where a formulary model relies on an “expected” patent expiration date. Three questions apply broadly: first, is the operative date set by a composition patent filed near the drug’s original approval, or by a later-filed or later-acquired secondary patent; second, has that secondary patent actually been tested in litigation and upheld, as opposed to merely existing unchallenged; and third, was the secondary patent originally invented by the reference company, or licensed or purchased from a third party after launch, since the latter pattern, as with Enbrel’s Roche-originated patents, has proven to be a repeatable and durable strategy across the industry.<\/p>\n\n\n\n

    Enbrel Is Not an Isolated Case<\/strong><\/h2>\n\n\n\n

    Humira vs. Enbrel: Different Mechanisms, Similar Outcome<\/strong><\/h3>\n\n\n\n

    AbbVie’s Humira followed a different path to a similar result. Rather than relying on two acquired patents and full-length litigation, AbbVie built and defended a much larger patent estate, which I-MAK’s 2025 update counts at 311 filed applications and 165 granted patents, providing what the group calculates as 43.3 years of protection, and then negotiated settlement dates with more than ten biosimilar makers that staggered U.S. launches to begin in 2023, years after European entry. [20] Enbrel’s estate is smaller by I-MAK’s count, but the two patents Amgen has actually litigated have proven just as durable as Humira’s much larger thicket, because only two have needed to hold up in court.<\/p>\n\n\n\n

    Revlimid’s Settlement-Driven Delay<\/strong><\/h3>\n\n\n\n

    Celgene, later Bristol Myers Squibb, took a third approach with the cancer drug Revlimid, settling with generic challenger Natco Pharma on a schedule that allowed limited-volume generic entry starting in 2022 and full-volume entry only in 2026, a negotiated rather than litigated extension. Enbrel differs from both precedents in one respect worth flagging to any team building a general patent-risk framework: its controlling exclusivity was purchased, not invented in-house and not negotiated away in settlement, and it has now survived two separate rounds of federal litigation testing that exact origin story.<\/p>\n\n\n\n

    Key Takeaways<\/strong><\/h2>\n\n\n\n
      \n
    • Enbrel’s original composition patent expired around 2010-2012, but two patents Amgen licensed from Roche in 2004 and later saw issued in 2011, the ‘182 and ‘522 patents, pushed U.S. exclusivity to April 2029.<\/li>\n\n\n\n
    • Two FDA-approved biosimilars, Erelzi (approved 2016) and Eticovo (approved 2019), remain under permanent injunction and have never launched in the U.S.<\/li>\n\n\n\n
    • Federal courts upheld the ‘182 and ‘522 patents against direct invalidity challenges in 2019-2021, and a separate antitrust challenge to how Amgen acquired those patents was dismissed in February 2026 and is now on appeal to the Fourth Circuit.<\/li>\n\n\n\n
    • I-MAK counts 154 U.S. patent applications and 74 granted patents on Enbrel as of 2025, though only two of those patents have actually been litigated to an enforced injunction against biosimilars.<\/li>\n\n\n\n
    • European biosimilar entry in 2016 cut prices by nearly half and captured about 40 percent market share within two years; no U.S. biosimilar has been able to test that same effect.<\/li>\n\n\n\n
    • April 2029 is the defensible planning date for U.S. etanercept biosimilar entry as of late 2026, with a pending Fourth Circuit appeal as the only live variable that could move it earlier.<\/li>\n<\/ul>\n\n\n\n

      FAQ<\/strong><\/h2>\n\n\n\n

      When can Erelzi or Eticovo actually launch in the United States?<\/strong>
      Not before U.S. Patent 8,163,522 expires on April 24, 2029, unless a court reverses the current injunctions or Amgen settles with Sandoz or Samsung Bioepis before then. [7][4]<\/p>\n\n\n\n

      Why did Enbrel’s patent protection extend so far past its original expiration?<\/strong>
      Amgen licensed, and later obtained exclusive rights to, two patent applications originally filed by Hoffmann-La Roche. Those applications issued as U.S. patents in 2011 and shortly after, with 17-year terms running from their issue dates rather than from Enbrel’s 1998 launch or its original 1990s-filed composition patent. [1]<\/p>\n\n\n\n

      Is Sandoz’s 2025 antitrust lawsuit still active?<\/strong>
      Yes. A Virginia federal court dismissed it in February 2026, and Sandoz appealed to the Fourth Circuit in March 2026. The appeal was still pending as of mid-2026, with industry groups and a retired Federal Circuit judge filing briefs opposing Sandoz. [4][19]<\/p>\n\n\n\n

      How many patents does Amgen hold on Enbrel?<\/strong>
      I-MAK’s most recent public count, from February 2025, is 154 U.S. patent applications filed, with 74 granted. Only two of those granted patents, the ‘182 and ‘522 patents, have been enforced against biosimilars in litigation. [20]<\/p>\n\n\n\n

      Did Enbrel ever face biosimilar competition anywhere?<\/strong>
      Yes, in the European Union, where the relevant patent expired earlier. Biosimilars launched there in early 2016, cutting prices by close to half and reaching roughly 40 percent market share within two years. [2][6]<\/p>\n\n\n\n

      What is the Noerr-Pennington doctrine, and why did it matter here?<\/strong>
      It is a legal doctrine holding that petitioning the government, including filing and enforcing patent lawsuits, is generally immune from antitrust liability. The Virginia district court relied on it in part to dismiss Sandoz’s 2026 antitrust claim against Amgen’s patent-acquisition and enforcement conduct. [4]<\/p>\n\n\n\n

      What is a “compulsory counterclaim,” and why did it sink Sandoz’s antitrust case?<\/strong>
      Federal Rule of Civil Procedure 13(a) requires a defendant to raise, within the original lawsuit, any counterclaim that arises from the same transaction or occurrence as the plaintiff’s claim, or lose the right to raise it later. The district court found Sandoz’s antitrust theory about Amgen’s Roche patent acquisition should have been raised inside the original 2016-2020 infringement case, not filed as a new lawsuit five years later. [4]<\/p>\n\n\n\n

      How much has the U.S. delay cost Medicare and Medicaid?<\/strong>
      I-MAK’s 2018 analysis of CMS data found combined Medicare and Medicaid spending on Enbrel rose 129 percent between 2012 and 2016 alone, totaling $7.7 billion in that four-year window. [2][8]<\/p>\n\n\n\n

      Could Amgen and Sandoz still settle before 2029?<\/strong>
      It is possible. Settlement, rather than litigating to the injunction date, is how many other biosimilar and generic disputes have resolved, including Humira’s staggered 2023 biosimilar launches. No settlement has been reported for Erelzi or Eticovo as of this writing.<\/p>\n\n\n\n

      Where can formulary and market-access teams track this in real time?<\/strong>
      Patent expiration dates, litigation status, and exclusivity timelines for etanercept and comparable biologics can be tracked through DrugPatentWatch’s patent and exclusivity database, which maintains current filings alongside FDA approval and biosimilar status data. [22]<\/p>\n\n\n\n

      Methodology<\/strong><\/h2>\n\n\n\n

      Data Sources<\/strong><\/h4>\n\n\n\n

      This article draws on primary sources where available: Amgen’s own press release announcing the ‘182 patent’s issuance, federal court case numbers and rulings as reported in legal-industry publications (JD Supra, Pearce IP, IPWatchdog, Citeline), FDA approval announcements, and I-MAK’s published patent-count reports and underlying methodology notes. Secondary sources (Fierce Pharma, GaBI Online, Center for Biosimilars, Healio, BioPharma Dive) were used to corroborate dates and figures and to source direct quotations attributed to named individuals or companies.<\/p>\n\n\n\n

      Time Period Analyzed<\/strong><\/h4>\n\n\n\n

      The timeline covers Enbrel’s 1998 U.S. launch through the most recent confirmed litigation development as of this writing, the July 2026 amicus filings in Sandoz’s Fourth Circuit appeal. Financial and pricing figures are drawn from the years in which each cited source reported them and are not adjusted or extrapolated forward.<\/p>\n\n\n\n

      Limitations<\/strong><\/h4>\n\n\n\n

      I-MAK’s patent counts (57 in 2018; 154 applications, 74 granted, in 2025) come from the organization’s own search methodology, which an October 2025 IPWatchdog critique argues may overstate the number of patents that meaningfully extend commercial exclusivity. This article reports both the raw counts and that critique, and separately identifies the two specific patents, the ‘182 and ‘522 patents, that courts have actually enforced against biosimilars, since those two carry far more predictive weight for a formulary timeline than the full patent count. The status of Sandoz’s Fourth Circuit appeal reflects the most recent reporting available as of this writing; readers should confirm current docket status before finalizing budget models, since appellate rulings can issue with little advance notice.<\/p>\n\n\n\n

      References<\/strong><\/h2>\n\n\n\n
        \n
      1. Amgen. (2011, November 22). Enbrel (etanercept) patent issued<\/em> [Press release]. https:\/\/www.amgen.com\/newsroom\/press-releases\/2011\/11\/enbrel-etanercept-patent-issued<\/li>\n\n\n\n
      2. I-MAK. (2018, November 30). Overpatented, Overpriced: Enbrel Special Edition<\/em> [Report]. https:\/\/www.i-mak.org\/wp-content\/uploads\/2018\/12\/i-mak.enbrel.report-2018-11-30F.pdf<\/li>\n\n\n\n
      3. PharmaDossier. (2026). Enbrel biosimilars compared: FDA approvals, patent litigation, and the 2029 market entry<\/em>. https:\/\/pharmadossier.com\/blog\/enbrel-biosimilars-compared<\/li>\n\n\n\n
      4. BiologicsHQ \/ Venable LLP. (2026, March 2). Court dismisses Sandoz’s Enbrel (etanercept) antitrust lawsuit<\/em>. https:\/\/biologicshq.com\/court-dismisses-sandozs-enbrel-etanercept-antitrust-lawsuit\/<\/li>\n\n\n\n
      5. Pearce IP. (2026, March 24). Sandoz appeals US court’s dismissal of antitrust claim against Amgen relating to biosimilar etanercept<\/em>. https:\/\/www.pearceip.law\/2026\/03\/13\/sandoz-appeals-us-courts-dismissal-of-antitrust-claim-against-amgen-relating-to-biosimilar-etanercept\/<\/li>\n\n\n\n
      6. Pharmaceutical Technology. (2025, April 14). Sandoz challenges Amgen’s Enbrel patents in US antitrust lawsuit<\/em>. https:\/\/www.pharmaceutical-technology.com\/news\/sandoz-challenges-amgens-enbrel-patents-in-us-antitrust-lawsuit\/<\/li>\n\n\n\n
      7. GaBI Online. (2021). Etanercept biosimilars delayed until 2029 in US<\/em>. https:\/\/www.gabionline.net\/biosimilars\/news\/etanercept-biosimilars-delayed-until-2029-in-us<\/li>\n\n\n\n
      8. Center for Biosimilars. (2020, September 8). Amgen filed nearly 3 times more patents on Enbrel in US than EU or Japan, report finds<\/em>. https:\/\/www.centerforbiosimilars.com\/view\/amgen-filed-nearly-3-times-more-patents-on-enbrel-in-us-than-eu-or-japan-report-finds<\/li>\n\n\n\n
      9. GaBI Online. (2021). US Supreme Court rejects Enbrel patent challenge from Sandoz<\/em>. https:\/\/www.gabionline.net\/biosimilars\/general\/us-supreme-court-rejects-enbrel-patent-challenge-from-sandoz<\/li>\n\n\n\n
      10. Wikipedia. Etanercept<\/em>. https:\/\/en.wikipedia.org\/wiki\/Etanercept<\/li>\n\n\n\n
      11. Springer \/ Rheumatology International. (2014). Etanercept biosimilars<\/em>. https:\/\/link.springer.com\/doi\/10.1007\/s00296-014-3080-5<\/li>\n\n\n\n
      12. Healio. (2016, September 13\/August 30). FDA approves biosimilar to Enbrel<\/em>. https:\/\/www.healio.com\/news\/rheumatology\/20160913\/fda-approves-biosimilar-to-enbrel<\/li>\n\n\n\n
      13. Fierce Pharma. (2021, December). Amgen stalls Samsung’s Enbrel biosim until 2029 in 2nd patent win of the year<\/em>. https:\/\/www.fiercepharma.com\/pharma\/amgen-stalls-samsung-s-enbrel-biosim-until-2029-second-patent-win-year<\/li>\n\n\n\n
      14. Healio. (2021, May 17). Supreme Court declines to hear Sandoz’s appeal for Enbrel biosimilar, upholds Amgen patent<\/em>. https:\/\/www.healio.com\/news\/rheumatology\/20210517\/supreme-court-declines-to-hear-sandozs-appeal-for-enbrel-biosimilar-upholds-amgen-patent<\/li>\n\n\n\n
      15. Stocktwits. (2026, March 5). Sandoz files antitrust lawsuit against Amgen over inflammation drug, seeks damages<\/em>. https:\/\/stocktwits.com\/news-articles\/markets\/equity\/sandoz-files-antitrust-lawsuit-against-amgen-seeks-damages\/chfCP48Rbac<\/li>\n\n\n\n
      16. Fierce Pharma. (2025, April 14). Sandoz takes Amgen to court again, challenging its patents on decades-old Enbrel<\/em>. https:\/\/www.fiercepharma.com\/pharma\/sandoz-takes-amgen-court-again-challenging-its-patents-enbrel<\/li>\n\n\n\n
      17. JD Supra \/ Venable LLP. (2026, March 9). Court dismisses Sandoz’s Enbrel (etanercept) antitrust lawsuit<\/em>. https:\/\/www.jdsupra.com\/legalnews\/court-dismisses-sandoz-s-enbrel-r-9820687\/<\/li>\n\n\n\n
      18. Citeline Generics Bulletin. (2026, March 16). ‘Our case is about standing up to patent abuse’ – Sandoz appeals Amgen etanercept antitrust ruling<\/em>. https:\/\/insights.citeline.com\/generics-bulletin\/legalandip\/our-case-is-about-standing-up-to-patent-abuse-sandoz-appeals-amgen-etanercept-antitrust-ruling-W2GGV6LL6RH6ZHSH4DWWQSKOMU\/<\/li>\n\n\n\n
      19. IPWatchdog. (2026, July 9). Judge Michel, other amici file briefs opposing Sandoz’s Fourth Circuit appeal in Enbrel antitrust case<\/em>. https:\/\/ipwatchdog.com\/2026\/07\/09\/judge-michel-other-amici-file-briefs-opposing-sandozs-fourth-circuit-appeal-in-enbrel-antitrust-case\/<\/li>\n\n\n\n
      20. I-MAK. (2025, February 21). Investigating the pharmaceutical industry’s drug patenting practices<\/em>. https:\/\/www.i-mak.org\/2025\/02\/21\/investigating-the-pharmaceutical-industrys-drug-patenting-practices\/<\/li>\n\n\n\n
      21. IPWatchdog. (2025, October 21). Counting patents, not progress: Another misdiagnosis by I-MAK<\/em>. https:\/\/ipwatchdog.com\/2025\/10\/21\/counting-patents-not-progress-misdiagnosis-i-mak\/<\/li>\n\n\n\n
      22. DrugPatentWatch. Drug patent strategy: The definitive guide for pharmaceutical IP teams, R&D leads, and institutional investors<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/optimizing-your-drug-patent-strategy-a-comprehensive-guide-for-pharmaceutical-companies\/<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

        Enbrel’s first composition patent expired in 2010. The drug is still exclusive in the United States sixteen years later, and […]<\/p>\n","protected":false},"author":1,"featured_media":39692,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39691","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39691"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39691\/revisions"}],"predecessor-version":[{"id":39693,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39691\/revisions\/39693"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39692"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}